Flexible Flat-Rate Plans
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
DrugPatentWatch Database Preview
Ticagrelor - Generic Drug Details
« Back to Dashboard
This ingredient has two hundred and fifteen patent family members in forty-four countries.
There are eighteen drug master file entries for ticagrelor. Three suppliers are listed for this compound.
Summary for Generic Name: ticagrelor
| Tradenames: | 1 |
| Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: see list | 18 |
| Suppliers / Packaging: see list | 3 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
Pharmacology for Ingredient: ticagrelor
| Drug Class | P2Y12 Platelet Inhibitor |
| Mechanism of Action | Phenylalanine Hydroxylase Activators P2Y12 Receptor Antagonists Cytochrome P450 3A4 Inhibitors Cytochrome P450 3A5 Inhibitors P-Glycoprotein Inhibitors |
| Physiological Effect | Decreased Platelet Aggregation |
Clinical Trials for: ticagrelor
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET;ORAL | 022433-001 | Jul 20, 2011 | RX | Yes | 6,525,060 | Dec 2, 2019 | Y | Y | ||||||||||||||||||
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET;ORAL | 022433-002 | Sep 3, 2015 | RX | No | 6,251,910 | Jul 15, 2018 | Y | |||||||||||||||||||
Astrazeneca Lp | BRILINTA | ticagrelor | TABLET;ORAL | 022433-001 | Jul 20, 2011 | RX | Yes | 6,251,910 | Jul 15, 2018 | Y | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Non-Orange Book Patents for Generic Ingredient: ticagrelor
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,974,868 | Compounds | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
International Patent Family for Ingredient: ticagrelor
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norway | 323780 | <disabled in preview> | |||||||||||||||||||||||||||
| Slovenia | 1386921 | <disabled in preview> | |||||||||||||||||||||||||||
| European Patent Office | 1135391 | <disabled in preview> | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Supplementary Protection Certificates for Tradename: TICAGRELOR
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011 00013 | Denmark | <disabled> | |||||||||||||||||||||||||||
| 90009-9 | Sweden | <disabled> | PRODUCT NAME: TICAGRELOR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV; REG. NO/DATE: EU/1/10/655/001-006 20101203 | ||||||||||||||||||||||||||
| 00485 | Netherlands | <disabled> | PRODUCT NAME: TICAGRELOR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/10/655/001-006 20101203 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
For more information try a trial or see the database preview and plans and pricing
How are People Using DrugPatentWatch?
To identify drugs that are coming off of patent
— Data analyst, USA
To understand various drug patents throughout the world
— Business development manager, India
To check for Australian drug patents
— Big Pharma, Ireland
To find generic producers around the world for specific active ingredients.
— Pharmaceutical wholesaler, Estonia
To identify drugs going off patent in the next five years
— Pharmaceutical product development coordinator, Indonesia
To check antibiotic drug patent information
— Pharmacist, Denmark
To know the patent expiration dates of branded pharmaceuticals products
— Pharmacist, USA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639
